AP2014007794A0 - Benzyl sulfonamide derivatives useful as mogat-2 inhibitors - Google Patents

Benzyl sulfonamide derivatives useful as mogat-2 inhibitors

Info

Publication number
AP2014007794A0
AP2014007794A0 AP2014007794A AP2014007794A AP2014007794A0 AP 2014007794 A0 AP2014007794 A0 AP 2014007794A0 AP 2014007794 A AP2014007794 A AP 2014007794A AP 2014007794 A AP2014007794 A AP 2014007794A AP 2014007794 A0 AP2014007794 A0 AP 2014007794A0
Authority
AP
ARIPO
Prior art keywords
mogat
inhibitors
derivatives useful
sulfonamide derivatives
benzyl sulfonamide
Prior art date
Application number
AP2014007794A
Other languages
English (en)
Inventor
Maria Carmen Fernandez
Lance Allen Pfeifer
Maria Rosario Gonzalez-Garcia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007794(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AP2014007794A0 publication Critical patent/AP2014007794A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AP2014007794A 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat-2 inhibitors AP2014007794A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06
PCT/US2013/022870 WO2013116075A1 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors

Publications (1)

Publication Number Publication Date
AP2014007794A0 true AP2014007794A0 (en) 2014-07-31

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007794A AP2014007794A0 (en) 2012-01-31 2013-01-24 Benzyl sulfonamide derivatives useful as mogat-2 inhibitors

Country Status (27)

Country Link
US (1) US8575352B2 (https=)
EP (1) EP2809651B1 (https=)
JP (1) JP2015511232A (https=)
KR (1) KR20140106750A (https=)
CN (1) CN104066719B (https=)
AP (1) AP2014007794A0 (https=)
AR (1) AR089771A1 (https=)
AU (1) AU2013215468A1 (https=)
BR (1) BR112014018636A8 (https=)
CA (1) CA2859995A1 (https=)
CL (1) CL2014001861A1 (https=)
CO (1) CO7010839A2 (https=)
CR (1) CR20140322A (https=)
DO (1) DOP2014000178A (https=)
EA (1) EA201491276A1 (https=)
ES (1) ES2590929T3 (https=)
GT (1) GT201400167A (https=)
HK (1) HK1199025A1 (https=)
IL (1) IL233712A0 (https=)
MA (1) MA35886B1 (https=)
MX (1) MX2014008599A (https=)
PE (1) PE20141679A1 (https=)
PH (1) PH12014501711A1 (https=)
SG (1) SG11201404106QA (https=)
TW (1) TW201343629A (https=)
WO (1) WO2013116075A1 (https=)
ZA (1) ZA201404836B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
DK3307262T3 (da) 2015-06-15 2021-08-09 Nmd Pharma As Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
CA3126334A1 (en) 2019-01-11 2020-07-16 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
CA2587149C (en) * 2004-11-10 2010-02-02 Pfizer Inc. Substituted n-sulfonylaminobenzyl-2-phenoxyacetamide compounds
KR20090051778A (ko) * 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
US8232282B2 (en) * 2006-09-28 2012-07-31 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
MX2009004314A (es) * 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20110275647A1 (en) 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体

Also Published As

Publication number Publication date
HK1199025A1 (en) 2015-06-19
JP2015511232A (ja) 2015-04-16
IL233712A0 (en) 2014-09-30
AR089771A1 (es) 2014-09-17
MA35886B1 (fr) 2014-12-01
BR112014018636A2 (https=) 2017-06-20
EP2809651A1 (en) 2014-12-10
AU2013215468A1 (en) 2014-07-10
TW201343629A (zh) 2013-11-01
MX2014008599A (es) 2014-08-22
WO2013116075A1 (en) 2013-08-08
CA2859995A1 (en) 2013-08-08
EP2809651B1 (en) 2016-06-29
CR20140322A (es) 2014-08-25
CO7010839A2 (es) 2014-07-31
GT201400167A (es) 2015-05-28
CL2014001861A1 (es) 2014-11-07
ES2590929T3 (es) 2016-11-24
CN104066719B (zh) 2016-08-24
PH12014501711A1 (en) 2014-10-13
SG11201404106QA (en) 2014-08-28
EA201491276A1 (ru) 2014-10-30
DOP2014000178A (es) 2014-08-31
BR112014018636A8 (pt) 2017-07-11
US20130197039A1 (en) 2013-08-01
US8575352B2 (en) 2013-11-05
ZA201404836B (en) 2017-08-30
PE20141679A1 (es) 2014-11-08
CN104066719A (zh) 2014-09-24
KR20140106750A (ko) 2014-09-03

Similar Documents

Publication Publication Date Title
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201409422B (en) Benzimidazole-proline derivatives
LT2841428T (lt) Dnr-pk inhibitoriai
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
ZA201408876B (en) Pyrrolotriazinone derivatives
IL233712A0 (en) Sulfonamide derivatives used as mogat–2 inhibitors
EP2870140B8 (en) Tetrahydroquinazolinone derivatives as parp inhibitors
LT2838883T (lt) Nauji feniltetrahidroizochinolino dariniai
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
IL235919A0 (en) inhibitors of fbxo3
ZA201405227B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
ZA201502878B (en) Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives